Approximately one-quarter of patients with metastatic castrate resistant prostate cancer (mCRPC) have alterations in homologous recombination repair (HRR), and these cancers exhibit increased sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors [2,3]. The gene discussed is PARP1; the disease is cancer.